https://www.europesays.com/ch/141623/ Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU) #(CSU) #(SD) #Approval #as #beyond #chronic #dermographism #expanding #FDA #first #for #Its #Novartis #receives #remibrutinib #Rhapsido® #spontaneous #symptomatic #treatment #urticaria #Use
#dermographism — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #dermographism, aggregated by home.social.